FDA approves Pfizer Booster for Kids 5 to 11, bypassing advisory panel.

After analysing data from an ongoing Pfizer research, the FDA decided to approve a third shot after finding that a subset of 67 children in this age range had greater antibody levels one month after getting a booster dose.
The FDA identified no new safety concerns and discovered that the youngsters suffered the same moderate side effects as other persons after taking a booster. Swelling at the injection site, weariness, headache, muscle or joint discomfort, chills, and fever are some of the adverse effects.
A meeting of the Centers for Disease Control and Prevention’s committee of independent vaccination experts was expected for Thursday, at which they will offer a recommendation for or against boosters.
Before approving the booster dose, the FDA did not convene CDC’s committee to discuss the evidence. Some committee members are frustrated that the FDA has frequently pushed through with booster dosage recommendations without conducting open public hearings.
Yesterday, May 19 2022,  CDC’s  Advisory Committee on Immunization Practices published COVID-19 vaccine safety updates: Primary series in children ages 5–11 years.